As a follow-up to our previous work characterizing the presence and role of AR-SVs in HCC sexual dimorphism, we sought to better understand downstream AR/AR-SV signaling and evaluate niclosamide, an anthelmintic drug that was recently the focus of repurposing efforts in AR-SV-driven PCa, for use as a therapeutic tool for AR-SV(±) HCC [5,32]. This evidence concerns the gene AR and hepatocellular carcinoma.